The Bristol-Myers Squibb Foundation’s commitment to address health disparities in cancer outcomes and care was represented at the Biden Cancer Initiative event at AACR. In 2016, the Foundation joined the Cancer Moonshot initiative and donated $25M to grantee projects to expand community-based cancer care resources and patient engagement and support programs for racial and ethnic minorities, rural, low income and vulnerable populations in the U.S. Grantee projects are being implemented in over 25 states across the country.
The Company’s Environmental efforts honored for the fourth consecutive year
NEW YORK, April 2, 2018 /3BL Media/ — The U.S Environmental Protection Agency (EPA) and the U.S. Department of Energy have recognized Bristol-Myers Squibb Company (NYSE: BMY) with an ENERGY STAR® Partner of the Year Sustained Excellence Award for outstanding efforts to improve the energy efficiency of facilities worldwide. Bristol-Myers Squibb has earned the ENERGY STAR® Partner of the Year award for the past four consecutive years.
Initiative focuses on improving patient transitions between primary and specialty care for populations affected by stroke, atrial-fibrillation and venous thromboembolism.
BALTIMORE, March 30, 2018 /3BL Media/ —The American Heart Association today announced the receipt of a $1.7 million grant from the Bristol-Myers Squibb Foundation that will address patient care across the care continuum. With this grant, the AHA will convene a task force representing the myriad of stakeholders in the patient care journey: cardiology specialty care providers, primary care providers, government, payer groups, and representatives of the patients we seek to serve.
By Murdo Gordon, Chief Commercial Officer, Bristol-Myers Squibb
To say that childhood cancer is profoundly disruptive doesn’t begin to scratch the surface of the impact the disease has on young patients and their families. The diagnosis changes everything in an instant. Then there is treatment, which often separates a young girl or boy from family and friends; from school; and from the life one knew or the life not yet really begun.
PRINCETON, N.J., March 9, 2018 /3BL Media/ - Employees at Bristol-Myers Squibb Company (NYSE: BMY) work passionately to advance science for patients with serious diseases, and now its U.S. employees are being given expanded paid time off for critical life events including caregiving for seriously ill family members and the care of newborn, foster or adoptive children. The new, generous, inclusive family-friendly benefits launched this year are part of the company’s commitment to meeting the needs of its diverse workforce through an innovative, market-leading approach.
New fellowship will transform postgraduate training and career opportunities for African American life scientists in academia and the biopharmaceutical industry R&D.
WASHINGTON, D.C., February 28, 2018 /3BL Media/ -- UNCF today announced a partnership with Bristol-Myers Squibb (NYSE:BMY) to launch an innovative fellowship program in the life sciences that will transform the postgraduate training experience for African American scientists pursuing research careers in academic or biopharmaceutical industry research and development (R&D). Named in honor of Dr.
SIOUX FALLS, S.D., February 20, 2018 /3BL Media/ – Avera Health is pleased to announce that the Walking Forward Program, based in Rapid City, has been awarded a grant for over $1.6 million from the Bristol-Myers Squibb Foundation to increase lung cancer screening rates for high-risk smokers living in western South Dakota.
The award, which will be distributed over the course of three years (2018-2020), will fund Walking Forward’s research dedicated to increasing awareness of lung cancer prevention and access to advanced lung cancer screening technology.
Collaborative program to ensure more patients benefit from early detection tool
WASHINGTON, D.C., January 31, 2018 /3BL Media/ — LUNGevity Foundation announced the launch of Project ACTS – Increasing Adherence to CT Screening for lung cancer – a multi-stakeholder project funded by a grant from Bristol-Myers Squibb Foundation through their Bridging Cancer Care™ initiative. Project ACTS will develop and evaluate tools to promote stronger adherence to lung cancer screening protocols so that patients can fully benefit from potentially life-saving CT screening.
Bristol-Myers Squibb was named to Fortune’s World’s Most Admired Companies list as part of the magazine’s annual rankings. The company was No. 5 in the Pharmaceuticals category.
The list is put together based on responses from thousands of survey participants. Fortune notes the companies featured on the World’s Most Admired list “represent the pinnacle of excellence in nine key performance areas, from investment value to social responsibility.”
Company ranks in top 10% of Pharmaceutical and Biotech Sector on the issues Americans care about most.
NEW YORK, December 14, 2017 /3BL Media/ -- Bristol-Myers Squibb Company (NYSE: BMY) was named one of America’s Most JUST Companies, according to Forbes and JUST Capital, a nonprofit that ranks the largest publicly traded corporations in the United States on the issues Americans care about most. The company ranked third in the Pharmaceutical & Biotech sector and 32nd overall out of 1,000 of the largest publicly-traded companies in the United States.